Precipio Competitors and Similar CompaniesClear all

Precipio's competitors and similar companies include nRichDX, MDxHealth and Nucleix.

	Precipio Precipio (formerly Transgenomic) is a company operating as a cancer diagnostics reference laboratory providing products and services to the oncology market.	nRichDX nRichDX is a biotech company providing liquid biopsy sample preparation for molecular testing.	MDxHealth MDxHealth is a molecular diagnostics company that develops and commercializes tests for cancer and other urologic diseases diagnosis.	Nucleix Nucleix is a company that develops, manufactures, and markets non-invasive molecular cancer diagnostic tests.
Founding Date	Founding Date 1997	Founding Date N/A	Founding Date 2003	Founding Date 2008
Type	Type Public	Type Private	Type Public	Type Private
Tags	Tags Healthcare biotech medical devices medical diagnostics oncology	Tags Healthcare biotech platform	Tags Healthcare biotech medical devices medical diagnostics oncology	Tags Healthcare biotech medical devices medical diagnostics oncology
Locations	Locations Omaha, US HQ Glasgow, GB New Haven, US Omaha, US	Locations Irvine, US HQ	Locations Herstal, BE HQ Nijmegen, NL Irvine, US Plano, US	Locations Rehovot, IL HQ San Diego, US
Employees	Employees 4235% increase	Employees 18	Employees 252	Employees 72
Valuation ($)	Valuation ($) 9.3 m	Valuation ($) N/A	Valuation ($) 93.5 m	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) $24m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) $107.9m (FY, 2025)	Revenue (est.) N/A
Cost of goods	Cost of goods $13.3m (FY, 2025)	Cost of goods N/A	Cost of goods $36.1m (FY, 2025)	Cost of goods N/A
Gross profit	Gross profit $10.7m (FY, 2025)	Gross profit N/A	Gross profit $71.8m (FY, 2025)	Gross profit N/A
Net income	Net income ($363k) (FY, 2025)	Net income N/A	Net income ($33.5m) (FY, 2025)	Net income N/A
Funding
Total funding raised	Total funding raised $ 1.5m	Total funding raised N/A	Total funding raised $ 1.1m	Total funding raised $ 61m